That brings Sanofi’s attorney fees, expenses and interest to a grand total of more … The FCA suit stems from patent infringement litigation Aventis Pharma SA had … Amphastar had originally argued that it wasn’t infringing the patent.
That brings Sanofi’s attorney fees, expenses and interest to a grand total of more … The FCA suit stems from patent infringement litigation Aventis Pharma SA had … Amphastar had originally argued that it wasn’t infringing the patent.